Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Ultragenyx Pharmaceutical Inc. buy The Goldman Sachs Group, Inc.

Start price
€46.20
02.08.24 / 50%
Target price
€69.62
02.08.25
Performance (%)
-46.75%
End price
€24.60
03.08.25
Summary
This prediction ended on 03.08.25 with a price of €24.60. The BUY prediction by The_Goldman_Sachs_Gr for Ultragenyx Pharmaceutical Inc. performed very badly with a performance of -46.75%. The_Goldman_Sachs_Gr has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Ultragenyx Pharmaceutical Inc. -7.895% -7.895% -34.579%
iShares Core DAX® -0.793% 4.201% 19.951%
iShares Nasdaq 100 -2.376% 0.857% 4.704%
iShares Nikkei 225® -2.701% -0.147% 12.609%
iShares S&P 500 -1.689% 1.244% 3.144%

Comments by The_Goldman_Sachs_Gr for this prediction

In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Prediction Buy
Perf. (%) -46.75%
Target price 69.624
Change
Ends at 02.08.25

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $67.00 to $76.00. They now have a "buy" rating on the stock.
Ratings data for RARE provided by MarketBeat

In the thread Trading Ultragenyx Pharmaceutical Inc.
Prediction Buy
Perf. (%) -46.75%
Target price 69.624
Change
Ends at 02.08.25

Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten

Stopped prediction by The_Goldman_Sachs_Gr for Ultragenyx Pharmaceutical Inc.

buy
Ultragenyx Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€40.80
06.06.24
€61.55
06.06.25
-21.08%
07.06.25